Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 13/20 | 0.56 |
| ▸ | TACR3 | P29371 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | FPR1 | P21462 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5440396 | 0.95 | F10 (0.58) | F10TACR3MAPTF2ALDH1A1 | |
| SCHEMBL5431479 | 0.92 | F10 (0.62) | F10TACR3MAPTF2ALDH1A1 | |
| SCHEMBL5431679 | 0.90 | F10 (0.51) | F10TACR3MAPTALDH1A1 | |
| SCHEMBL5446696 | 0.88 | F10 (0.51) | F10TACR3MAPTALDH1A1FPR1 | |
| SCHEMBL5440627 | 0.88 | F10 (0.53) | F10MAPTF2ALDH1A1HPGD | |
| SCHEMBL5432971 | 0.88 | F10 (0.50) | F10TACR3MAPTALDH1A1 | |
| SCHEMBL5432974 | 0.88 | F10 (0.50) | F10TACR3MAPTF2ALDH1A1 | |
| SCHEMBL5433072 | 0.86 | F10 (0.58) | F10TACR3MAPTF2ALDH1A1 | |
| SCHEMBL5440568 | 0.86 | F10 (0.60) | F10TACR3MAPTALDH1A1CYP1A2 | |
| SCHEMBL5485116 | 0.86 | F10 (0.60) | F10TACR3MAPTALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070129361-A1 | LACTAM-CONTAINING DIAMINOALKYL, Beta-AMINOACIDS, Alpha-AMINOACIDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | QIAO JENNIFER X | 2007-06-07 | — | — | US | claimed |
| US-20070185079-A1 | Therapeutic agents I | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
| US-20070129361-A1 | LACTAM-CONTAINING DIAMINOALKYL, Beta-AMINOACIDS, Alpha-AMINOACIDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | QIAO JENNIFER X | 2007-06-07 | — | — | US | disclosed |
| CN-1906169-A | Therapeutic agents I | ASTRAZENECA AB (SE) | 2007-01-31 | — | — | CN | disclosed |
| EP-1706384-A1 | THERAPEUTIC AGENTS I | AstraZeneca AB (SE) | 2006-10-04 | — | — | EP | disclosed |
| WO-2005066132-A1 | THERAPEUTIC AGENTS I | ASTRAZENECA AB (SE) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129361-A1 | LACTAM-CONTAINING DIAMINOALKYL, Beta-AMINOACIDS, Alpha-AMINOACIDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | PEPD, XPNPEP1, METAP1 | F10 46/4885TACR3 2543/4885MAPT 4212/4885 |
| US-20070185079-A1 | Therapeutic agents I | HTT, GRIN2A, GRIN1 | F10 2780/4885TACR3 1654/4885MAPT 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.